Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriasis AND Plaque Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    416 result(s) found for: Psoriasis AND Plaque Psoriasis. Displaying page 9 of 21.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2022-001631-82 Sponsor Protocol Number: EDP2939-101 Start Date*: 2022-11-29
    Sponsor Name:Evelo Biosciences, Inc.
    Full Title: A Phase 1/2, randomised, placebo-controlled study of EDP2939 in healthy volunteers and participants with moderate plaque psoriasis.
    Medical condition: Moderate plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002433-22 Sponsor Protocol Number: I1F-MC-RHBF Start Date*: 2015-11-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study with a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long Term Efficacy and Safety of Ixeki...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) CZ (Completed) GB (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000904-14 Sponsor Protocol Number: M19-164 Start Date*: 2019-11-26
    Sponsor Name:AbbVie
    Full Title: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to ...
    Medical condition: Plaque Psoriasis / Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020003-73 Sponsor Protocol Number: A3921079 Start Date*: 2011-03-31
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 USA
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000859-14 Sponsor Protocol Number: CC-10004-PSOR-010 Start Date*: 2013-01-17
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to...
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) CZ (Completed) LV (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020005-32 Sponsor Protocol Number: A3921111 Start Date*: 2011-02-08
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVE...
    Medical condition: Chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001855-11 Sponsor Protocol Number: CAIN457AGB01 Start Date*: 2013-09-06
    Sponsor Name:Novartis Pharmaceuticals UK Limited
    Full Title: Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFα antaGoNists: A clinical Trial EvalUating Treatment REsults
    Medical condition: Moderate to severe active, chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003331-38 Sponsor Protocol Number: I1F-MC-RHCD Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Multicenter, Double-Blind, Randomized, Active- and Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderat...
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) PL (Completed) HU (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003022-40 Sponsor Protocol Number: UKM14_0008 Start Date*: 2015-03-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003427-30 Sponsor Protocol Number: PS0014 Start Date*: 2018-09-20
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004611-38 Sponsor Protocol Number: AV002 Start Date*: 2018-10-09
    Sponsor Name:Bond Avillion 2 Development LP
    Full Title: A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with mo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-000190-12 Sponsor Protocol Number: I1F-MC-RHBP Start Date*: 2015-07-09
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-000276-34 Sponsor Protocol Number: CAIN457F2306 Start Date*: 2011-08-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years ...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) GB (Completed) DE (Completed) BG (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003209-22 Sponsor Protocol Number: UNI50001-203 Start Date*: 2022-02-09
    Sponsor Name:UNION therapeutics A/S
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate-to-severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004998-13 Sponsor Protocol Number: LP0160-1329 Start Date*: 2020-06-02
    Sponsor Name:LEO Pharma A/S
    Full Title: Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight
    Medical condition: moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003286-10 Sponsor Protocol Number: I6T-MC-AMAJ Start Date*: 2018-05-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed) CZ (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000839-33 Sponsor Protocol Number: LP0053-1108 Start Date*: 2016-03-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety and Effect of LEO 90100 aerosol foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) with Plaque Psoriasis A phase 2 trial evaluating the safety and e...
    Medical condition: Plague Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004687-47 Sponsor Protocol Number: M10-255 Start Date*: 2008-04-02
    Sponsor Name:Abbott GmbH & Co. K.G.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety and Efficacy of ABT-874 to Methotrexate in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) ES (Completed) FR (Completed) AT (Completed) BE (Completed) DK (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003299-30 Sponsor Protocol Number: I6T-MC-AMAH Start Date*: 2018-12-11
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) FR (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013072-52 Sponsor Protocol Number: M04-717 Start Date*: 2011-05-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicentre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) Outside EU/EEA NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:55:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA